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Protein misfolding and aggregation is the hallmark of numerous
human disorders, including Alzheimer’s disease. This process in-
volves the formation of transient and heterogeneous soluble olig-
omers, some of which are highly cytotoxic. A major challenge for
the development of effective diagnostic and therapeutic tools is
thus the detection and quantification of these elusive oligomers.
Here, to address this problem, we develop a two-step rational
design method for the discovery of oligomer-specific antibodies.
The first step consists of an “antigen scanning” phase in which an
initial panel of antibodies is designed to bind different epitopes
covering the entire sequence of a target protein. This procedure
enables the determination through in vitro assays of the regions
exposed in the oligomers but not in the fibrillar deposits. The
second step involves an “epitope mining” phase, in which a second
panel of antibodies is designed to specifically target the regions
identified during the scanning step. We illustrate this method in
the case of the amyloid β (Aβ) peptide, whose oligomers are asso-
ciated with Alzheimer’s disease. Our results show that this ap-
proach enables the accurate detection and quantification of Aβ
oligomers in vitro, and in Caenorhabditis elegans and mouse
hippocampal tissues.
Alzheimer’s disease | amyloid | protein aggregation | protein design
Alzheimer’s disease (AD), which is the most prevalent causeof dementia, affects over 50 million people worldwide (1). A
molecular hallmark of AD is the accumulation of insoluble
protein deposits, most notably amyloid plaques and neurofibril-
lary tangles, in specific brain tissues (2–6). Amyloid plaques, in
particular, predominantly consist of aggregated forms of the
amyloid β peptide (Aβ) (2–6) and are formed through a complex
process that involves a variety of structurally different species (7,
8). Among such species, increasing evidence has implicated small,
soluble oligomers as major agents responsible for neurotoxicity in
AD (8–13). In particular, these oligomers have been shown to
trigger various toxic pathways, including synaptic dysregulation,
membrane permeabilization, oxidative stress, mitochondrial dys-
function, and activation of proinflammatory response (9, 11).
The conformational heterogeneity, low concentrations, and
transient nature of these oligomeric species have made their iso-
lation and characterization very challenging. Antibodies offer a
variety of opportunities to overcome this challenge, as they rep-
resent powerful and versatile tools, owing to their high binding
specificity and affinity and well-established discovery methods (14,
15). These protein molecules have highly successful applications in
diagnostics, therapeutics, and targeted drug delivery systems, for
infectious diseases, cancer, and metabolic and hormonal disorders
(16). In particular, many diagnostic tests routinely used in the
clinic are based on antibodies. For this reason, in the last 20 years
major efforts have been made to overcome the challenges in
isolating and stabilizing oligomeric species for immunization and
phage display protocols to develop antibodies that selectively
recognize such species in positron emission tomography scans and
biological samples from patients (11, 17–20).
Recently, we introduced a scanning method based on the use of
rationally designed, single-domain (VH) antibodies (DesAbs) for
sequence-activity relationship studies (21–23). Using this strategy,
we found that the antibody DesAb-Aβ29–36, targeting the epitope
29 to 36 of the 42-residue form of Aβ (Aβ42), inhibits the sec-
ondary nucleation step during the aggregation of Aβ42 at sub-
stoichiometric concentrations (Fig. 1B). This result suggests that
DesAb-Aβ29–36 binds to Aβ42 aggregates with higher affinity than
to monomers. Furthermore, recent structural characterizations of
Aβ42 amyloid fibrils have shown that the C-terminal region of this
peptide is buried within the core of the cross-β structure (24), and,
accordingly, DesAb-Aβ29–36 shows low binding toward mature fi-
brils (21). Taken together, these results indicate that DesAb-
Aβ29–36 inhibits secondary nucleation by interacting with oligo-
mers and residues 29 to 36 of Aβ42 is likely to be solvent-exposed
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when the peptide is oligomeric, before becoming buried in amy-
loid fibrils. Therefore, targeting epitopes in this region could
represent a strategy for generating oligomer-specific antibodies.
In this work, we use rational design to generate a battery of
DesAbs, targeting epitopes in the region of residues 29 to 36 of
Aβ42, and experimental screenings to identify one, DesAb-O,
which selectively binds oligomers of Aβ, rather than its mono-
meric and fibrillar forms (Fig. 1A). We characterize the binding
properties of DesAb-O in vitro and in complex mixtures from
animal models toward the development of diagnostic tools.
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Fig. 1. Rational design of a conformation-specific antibody for Aβ42 oligomers. (A) Schematic representation of the target selection strategy used in this
work, which aims to generate an antibody with higher affinity for Aβ42 oligomers than monomers or fibrils. (B) Representation of the aggregation
mechanism of Aβ42 (8). Primary nucleation (kn), secondary nucleation (k2), and elongation (k+) rate constants are shown. The red arrow indicates secondary
nucleation processes, which are primarily responsible for the production of oligomers (21). (C) Sequence of Aβ42; the color gradient provides a visual rep-
resentation of the results of the antigen scanning phase, where red residues are increasingly more effective targets for binding Aβ42 oligomers; the initial
methionine residue is not shown. In the epitope mining phase, six designed complementary peptides (Left) targeting the region of residues 29 to 36 in the
Aβ42 sequence were used to generate six single-domain antibodies, whose CDR3 sequences are shown together with their corresponding Aβ42 epitopes
(Right). The sequence of the complementary peptide of DesAb-O, the designed antibody with highest binding affinity for Aβ oligomers, is shown in red on the
right-hand side. (D) ThT-based in vitro aggregation assay of 3 μM Aβ42 (three replicates are shown). The purple dashed line indicates the time at which
samples were collected from the aggregation reaction to perform the ELISA experiment. a.u., arbitrary units. (E) ELISA experiment performed on samples
collected from the aggregation reaction shown in B, using the six DesAbs as primary antibodies. For each antibody, absorbance values recorded in the
presence of Aβ42 aggregated samples were normalized over background absorbance values (i.e., in the presence of BSA only). The bar corresponding to
DesAb-O is colored magenta while the one corresponding to the original DesAb-Aβ29–36 is green. The dashed line corresponds to the value of DesAb-Aβ29–36.
Error bars are representative of the SD. Statistical analysis was performed by ANOVA with multiple comparison (95% CI, **P ≤ 0.01).
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Results
Antibody Mining to Identify An Oligomer-Specific Antibody. Based
on our previous results (21), we performed a rational search for
complementary peptides binding epitopes in the region of residues
29 to 36. We thus designed a panel of six additional antibodies with
the aim of selecting the antibody with highest preferential binding
to Aβ42 oligomers with respect to monomers and fibrils (Fig. 1).
To do so, first we generated six complementary peptides, using the
cascade method (22) (Methods). In this method the complemen-
tary peptides are assembled from peptide fragments selected from
the Protein Data Bank (PDB), so that such fragments are com-
plementary to the corresponding short peptide fragments of the
target sequence because they are found in two opposing strands of
a β-sheet. We grafted these peptides into a human VH domain
antibody scaffold (20), and we expressed and purified the resulting
DesAbs in Escherichia coli as previously reported (21) (SI Appen-
dix, Fig. S1A). Circular dichroism (CD) spectroscopy revealed that
all six DesAbs have a secondary structure content compatible with
the native conformation of a VH domain (SI Appendix, Fig. S1B).
In order to identify the DesAbs with the strongest binding to
Aβ42 oligomers, we developed an enzyme-linked immunosorbent
assay (ELISA)-based screening assay (Fig. 1 C–E). We performed
our analysis on samples collected directly from aggregation reac-
tions at the half-time of aggregation (Fig. 1D), where the oligomers
are present at their highest concentration (25). We immobilized
these samples onto an ELISA plate and then used the various
DesAbs as primary antibodies in an indirect ELISA setup (Fig. 1 D
and E). We found that all of the antibodies in the panel were able
to bind to the oligomeric mixtures. In particular, the antibody
carrying the complementary peptide ESAFGRA, which we will
refer to as DesAb-O (SI Appendix, Fig. S1C), showed the strongest
binding (Fig. 1E).
Characterization of the Conformational Specificity of DesAb-O. Next,
in order to determine whether DesAb-O is specific for oligomers
over fibrils, we used total internal reflection fluorescence (TIRF)
microscopy to visualize individual aggregates in samples taken at
specific incubation times from aggregation reactions of 3 μM
Aβ42 (Fig. 2 and SI Appendix, Figs. S2 and S3). We performed a
colocalization analysis by depositing these protein samples on
glass slides and labeling them with two different fluorescent dyes:
5 μM thioflavin T (ThT), a generic dye for amyloid aggregates,
and 1 nM AF647-labeled DesAb-O (AF647-DesAb-O). We then
measured how many of the aggregates contained in the samples
were recognized by either ThT, AF647-DesAb-O, or both. We
found that many aggregates were probed by both ThT and
AF647-DesAb-O at early aggregation times, with a percentage of
coincidence instances up to 45% between 60 and 100 min
(Fig. 2 A and B). In contrast, at later incubation times (beyond
140 min), when mature amyloid fibrils are formed, the percent-
age of coincidence dramatically drops down to less that 10%.
To prove that, in these conditions, DesAb-O binds oligomers in
the presence of many other aggregated species, we further in-
vestigated the content of the samples at the single aggregate
nanoscale by acquiring high-resolution, three-dimensional (3D)
morphology maps using phase-controlled atomic force microscopy
(AFM) (26). We found that samples at 20, 80, and 240 min were
all highly heterogeneous and contained different types of aggre-
gated species (Fig. 2C). Starting from 80 min, we also observed the
presence of ring-shaped toroidal and prefibrillar oligomers, whose
size matches those recognized by DesAb-O and observed by TIRF.
In order to determine the sizes and shapes of the Aβ42 aggre-
gates recognized by DesAb-O, we performed super-resolution
imaging by direct stochastic optical reconstruction microscopy
(dSTORM) using AF647-DesAb-O on samples collected at
40 min of aggregation. These data show that DesAb-O binds Aβ42
aggregates that are significantly smaller than the diffraction limit
(∼230 nm; Fig. 2 D and E and Movie S1). On the contrary,
DesAb-O does not bind to late-stage (140 min) aggregates (Movie
S2), further confirming the specificity of the DesAb to oligomeric
species. Furthermore, DesAb-O was able to bind oligomers with
an apparent subnanomolar binding affinity, compared to the low
micromolar affinity for fibrils (Fig. 2F), as derived by microfluidic
diffusional sizing (27) (Fig. 3).
Taken together, these data indicate that DesAb-O is able to
preferentially bind oligomers over monomers and fibrils of Aβ42.
ELISA-Based Real-Time Oligomer Quantification Using DesAb-O.
Given the high oligomer specificity of DesAb-O, we developed
an assay to monitor the formation, conversion, and inhibition by
anti-amyloid molecules of oligomeric populations during the
aggregation of Aβ42. First, we examined Aβ42 oligomers formed
during in vitro aggregation assays (25). We used aggregation
reactions of 5 μM Aβ42, from which we extracted 20-μL samples
at specific incubation times. These samples were then analyzed
by an indirect ELISA set up using DesAb-O as primary antibody
(Fig. 4A and Methods).
In order to assess whether this antibody was able to detect
Aβ42 oligomers under our experimental conditions, we com-
pared its performance to that of a commercial antibody (6E10),
which targets the N-terminal region of Aβ42, and of a previously
described DesAb (DesAb-Aβ18–24) (21), which binds to all ag-
gregated species, oligomers, and fibrils with no particular pref-
erence, at the beginning (0 h), at the half-time (0.5 h), and at the
plateau (2 h) of aggregation (Fig. 4B). As expected, we observed
that 6E10 leads to similar signals at the three incubation times
(Fig. 4B, gray bars). As this antibody binds the N terminus of
Aβ42, which is a portion of the peptide exposed in most aggre-
gated conformations, this result proves that the total amount of
Aβ42 in the wells is similar for all three time points and the
presence of aggregates does not affect the absorption of the
samples on the ELISA wells. In contrast, the DesAb-Aβ18–24
signal increased with the aggregation time, demonstrating that
this antibody preferentially binds aggregated species but cannot
distinguish between oligomers and fibrils (Fig. 4B, blue bars, and
SI Appendix, Fig. S4). Finally, DesAb-O showed the highest
signal at the half-time of the aggregation reaction (Fig. 4B, red
bars), indicating that this antibody specifically binds oligomers,
which transiently form during the aggregation of Aβ42. In par-
ticular, the signal of DesAb-O was twofold higher at the half-time
than at the beginning of the aggregation. Notably, it has been
shown that the concentration of monomers is about 35-fold higher
than the concentration of oligomers (2.4 μM vs. 70 nM) at this
time point under the same aggregation conditions (8) (Fig. 4C).
We then performed a time-course experiment (Fig. 4 D and E)
to test whether we could characterize the time evolution of the
Aβ42 oligomer population during the aggregation process. To do
so, we prepared solutions of 3 μM Aβ42, and we monitored the
aggregation of Aβ42 by ThT (Fig. 4D) and by using DesAb-O as
primary antibody in ELISA experiments on different incubation
times of the aggregation reaction (Fig. 4E). We found that, in the
ELISA experiments, the absorbance from DesAb-O progressively
increased, reaching the highest value at 1 h of incubation, ap-
proximately at the half-time of aggregation as determined by ThT
(Fig. 4D), where oligomers are at their highest concentrations.
This value was approximately twofold higher than that initial ag-
gregation time points. After 1 h of incubation, the absorbance
progressively decreased to values even lower than the initial ones,
further indicating that DesAb-O does not bind fibrillar species
(Fig. 4E and SI Appendix, Fig. S4B).
Using DesAb-O to Assess Aβ42 Oligomer Inhibition by Drug Candidates.
Next, we evaluated the capability of the DesAb-O assay to capture
changes in the oligomeric population in the presence of anti-
amyloid compounds. To do so, we performed an aggregation
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assay in the presence of the small molecule bexarotene (Fig. 4 D
and E), which has been shown to inhibit primary nucleation and
thus to delay the formation of Aβ42 oligomers (28). In this case,
the DesAb-O–based ELISA detected a shift of 30 min in the peak
of the oligomers (Fig. 4E), which matches the shift in half-time of
aggregation observed by ThT assay (Fig. 4D). These results in-
dicate that our antibody-based assay is able to detect oligomeric
populations formed during in vitro aggregation of Aβ42 and that
this technique can be used to probe the effects of anti-amyloid
compounds on these populations.
DesAb-O Detects Aβ42 Oligomers in a Caenorhabditis elegans Model
of AD. In order to verify whether DesAb-O specifically detects
Aβ42 oligomers formed in vivo, we used a C. elegans model of
Aβ42-mediated dysfunction, called GMC101, in which human
Aβ42 is expressed in body wall muscle cells where it forms ag-
gregates and results in severe age-progressive paralysis (29). The
analysis was performed on protein extracts from 500 GMC101
worms at days 0, 3, 5, 7, and 10 of adulthood (Fig. 5 A and B).
We first assessed the fitness of the worms for 10 d starting at 24 h
of induction of aggregation (Methods). We found that the
GMC101 worms had the most dramatic drop of mobility
between days 5 and 7, which indicates that the toxic species likely
reach their highest concentrations at that time. Then, we moni-
tored the formation of the amyloid aggregates using the amyloid-
specific dye NIAD-4, whose fluorescence increases with the
concentration of amyloid aggregates. We found no significant
NIAD-4 fluorescence change able to capture the pathological
behaviors observed between days 5 and 7, suggesting that this
compound is not selective for toxic aggregates. Then, we verified
whether we were able to specifically detect these species using
DesAb-O. To do so, we analyzed protein samples from worms at
different days of adulthood by means of ELISA (Methods) and
compared the result of this experiment with a quantification of
the aggregates using NIAD-4. In particular, we coated the
ELISA wells with the protein extracts and used DesAb-O as a
primary antibody. As a control, we performed the same pro-
cedure on protein extracts from the wild-type C. elegans model
N2 and used these signals as a reference (Fig. 5A). We found
that DesAb-O was able to specifically recognize toxic Aβ42
species in the GMC101 protein extracts formed between days 5
and 7 that NIAD-4 is unable to detect.
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Fig. 2. Characterization of the conformational specificity of DesAb-O by TIRF, AFM, and dSTORM. (A) Coincidence of ThT and AF647-DesAb-O signals in the
TIRF single-molecule imaging of aggregates from an aggregation reaction of Aβ42. Three independent experiments in three different colors (black, red, and
violet) are shown. Each point is the average of 10 fields. Error bars represent the SD. (B) TIRF images at 80 and 240 min of aggregation time are shown. ThT,
AF647, and composite channel images are shown. (Scale bars, 20 μm.) (C) Wide (Top) and detailed (Bottom) high-resolution AFM 3D morphology maps of
samples at 0, 20, 80, and 240 min. (D) Super-resolution dSTORM imaging of an aggregation reaction of Aβ42 after 40 min of incubation. (Left) Diffraction
limited image. (Right) dSTORM image. (Scale bars, 2 μm in the lower-magnification images and 500 nm in the zoomed images.) (E) Representation of the
experimental setup for super-resolution imaging. (F) Estimation of the Kd values of binding of DesAb-O with different aggregated species of Aβ42.
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DesAb-O Quantifies Aβ42 Oligomers in Hippocampal Tissue in a Mouse
Model of AD. To further validate the ability of DesAb-O to detect
and quantify Aβ42 oligomers formed in vivo, we performed similar
analyses using a J20 mouse model of AD (PDGF-APPSw,Ind),
which overexpresses a variant of human amyloid precursor protein
carrying the Swedish and Indiana familiar mutations (30). We
performed ELISAs on hippocampus extracts using DesAb-O and
6E10, and quantified NIAD-4 fluorescence from tissue slices from
mice at 4, 9, and 18 mo of age. We then normalized these signals
using a control wild-type mouse. We were able to detect positive
signals of DesAb-O at 4 mo of age, when the mice show the initial
signs of memory impairment (31) and neuroinflammation and
synaptic deficit (32), but before amyloid deposits are significantly
detected with NIAD-4. Furthermore, the DesAb-O signal in-
creases between 4 and 9 mo and then decreases at 18 mo, while
both 6E10 and NIAD-4 signals progressively increase (Fig. 5 B–
E). The decrease of DesAb-O signal observed at 18 mo suggests
that the amounts of oligomers may decrease at this age. These
studies demonstrate that DesAb-O detects oligomers early in the
pathogenesis in this mouse model of AD and may provide a
valuable tool to assess oligomer load in the AD brain.
DesAb-O Detects Zinc-Stabilized Aβ40 Oligomers but Not Aβ40
Monomers and α-Synuclein Oligomers. Given that different types
of Aβ oligomers (33) are likely to exist upon in vivo aggregation, we
also tested the ability of DesAb-O to detect other types of Aβ olig-
omers. To this end, we carried out a fluorescence-based screening
assay in combination with Zn2+-stabilized Aβ40 oligomers (33). This
assay uses the fluorescent probe 8-anilinonaphthalene-1-sulfonic acid
(ANS), whose fluorescence emission increases upon binding to ex-
posed hydrophobic regions on the surface of oligomers. We thus
monitored the change in ANS fluorescence in the presence of a 1:1
ratio of DesAb:Aβ40 (SI Appendix, Fig. S5). We found that the
addition of the DesAbs decreased ANS fluorescence, suggesting it
prevents ANSmolecules from binding the surface of the oligomers as
a result of the antibody binding. Among all of the antibodies pro-
duced in this work, the antibody DesAb-O showed the greatest
binding in this experiment (SI Appendix, Fig. S6), significantly higher
than that of DesAb-Aβ29–36 (SI Appendix, Fig. S5). As a comple-
mentary measurement, we performed an ELISA (SI Appendix, Fig.
S6) monitoring the binding of immobilized DesAbs in the presence
of Aβ40 oligomer solution. We thus found that, while the majority of
the antibodies had a binding similar to the original antibody DesAb-
Aβ29–36, DesAb-O showed significantly stronger binding to Aβ40
oligomers (SI Appendix, Fig. S6).
We further confirmed these results with a dot blot analysis. To
do so, we immobilized the antibodies DesAb-O and the antibody
containing a complementary peptide (PYGSMYVHS), the latter
being the least reactive antibody in the ANS quenching experi-
ments on a nitrocellulose membrane (SI Appendix, Fig. S6). We
then incubated the membrane in the presence of a solution of
stabilized Aβ40 oligomers and revealed the bound oligomers
using 6E10, a commercial primary antibody targeting Aβ. In
agreement with the previous experiments, DesAb-O was the
antibody showing the strongest binding to Aβ40 oligomers.
Furthermore, we tested the anti-aggregation proprieties of this
antibody, as we previously did for DesAb29–36 (21). We found
that DesAb-O mainly affects the secondary nucleation of Aβ42
aggregation (SI Appendix, Fig. S7). This is in line with what we
observed for DesAb29–36, as both antibodies target the same
epitope of Aβ42. In the case of DesAb-O, however, the in-
hibitory effect is less strong, probably as a consequence of the
lower affinity for monomers and fibrils.
We then quantified the sequence and conformational specificity
of DesAb-O binding. In particular, we determined whether this
antibody was selective for stabilized Aβ40 oligomers over mono-
mers of Aβ40, and similarly whether it was specific for Aβ oligo-
mers over those formed by another amyloid protein, α-synuclein.
To do so we performed isothermal titration calorimetry (ITC)
experiments (SI Appendix, Fig. S8), where we measured the heat
change over time upon injections of the DesAbs into solutions
containing Zn2+-stabilized oligomers or monomers of Aβ40. We
found that DesAb-O binds oligomers with a dissociation constant
(Kd) of 440 ± 1.5 nM (SI Appendix, Fig. S8). We observed the
binding to be exothermic and enthalpically driven [ΔH = −1.27E4 ±
9.4E2 cal/mol; ΔS = −13.4 ± 9.4E2 cal/(mol·deg)]. The stoichi-
ometry of binding, DesAb-O:Aβ40 molecules (about 1:5), sug-
gests a binding of about one antibody per oligomer, in agreement
with a previous report, which suggest that these oligomers typi-
cally contain five Aβ40 monomers (33). The binding of DesAb-O
to monomers of Aβ40 was extremely weak and not quantifiable,
as well as the binding of DesAb-O to stabilized α-synuclein
oligomers (12), indicating that DesAb-O is both conformation-
and sequence-specific (SI Appendix, Fig. S8).
Discussion and Conclusions
Sequence-specific and conformation-specific antibodies capable
of binding neurotoxic protein oligomers are powerful tools for
basic research, as well as for diagnostic and therapeutic appli-
cations. These antibodies enable the quantification of the amounts
Fig. 3. Determination of the binding affinity of DesAb-O for Aβ42 amyloid
fibrils. We used microfluidic diffusion measurements to determine the af-
finity of DesAb-O for Aβ42 amyloid fibrils. The analysis yielded an effective
Kd of 1 μM, and the binding ratio of about 1 to 200 (DesAb-O:Aβ42) suggests
that DesAb-O binds the fibril ends, where the epitope Aβ4229–36 may not be
buried in the structural core of the fibrils.
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of oligomers present in given samples, and the characterization
of their properties and behavior. In particular, in combination
with fluorescence microscopy and with immunoassays such as
ELISA and related methods, antibodies offer unique possibilities
to assess the presence and abundance of oligomers in cells
and tissues.
The discovery of oligomer-specific antibodies, however, is very
challenging because of the transient nature of the oligomers
produced during protein aggregation reactions. These oligomers
are characteristically not sufficiently stable to be used as antigens
in standard in vivo or in vitro antibody discovery methods. To
overcome this challenge and contribute to the development of
oligomer-specific antibodies, we have presented a rational design
method that does not require previous knowledge of the struc-
ture of the target oligomers. The method involves two phases,
whereby an initial panel of antibodies is designed to bind dif-
ferent epitopes covering the entire sequence of a target protein
(scanning phase). Analysis of the antibodies in this panel enables
the identification of epitopes exposed in the oligomers but
mostly inaccessible in the fibrils. In the second step, a second
panel of antibodies is designed to target the epitopes identified
in the first step (mining phase). Further binding assays enable
the identification of the oligomer-specific antibody in the panel
with the highest binding affinity.
We have illustrated the application of this rational design
method for the determination of the oligomeric populations
formed during the aggregation of Aβ42 both in vitro and in vivo
using C. elegans and mouse models of AD. We anticipate that
this technology will create novel opportunities for the detection
and accurate quantification of oligomers of amyloidogenic pro-
teins for diagnostic and therapeutic applications.
Methods
Rational Design of the Antibodies.We summarize the rational method for the
identification of complementary peptides that bind to specific linear epitopes
in target proteins of interest, which we graft onto the CDR loops of domain
antibodies. A detailed description of the method is provided in ref. 22. The
complementary peptide design procedure consists of two steps. First, given a
target linear epitope, we collect from the PDB all protein fragments that
face in a β-strand any subsequence of at least three residues in which the
target epitope can be fragmented. Second, complementary peptides pre-
dicted to bind the target epitope are built by merging together these
fragments using the cascade method (22). In essence, in the cascade method
fragments are linked using three rules: 1) fragments can be joined together
only if found in β-strands of the same type (i.e., parallel or antiparallel), 2) all
fragments making up a complementary peptide must partly overlap with
their neighboring fragments, and 3) the overlapping regions must be
identical both in the sequence and in the backbone hydrogen-bond pattern
that is extracted from the β-strand where each fragment is found. Since the
identification of the complementary peptides is based on the analysis of
amino acid sequences facing each other in β-strands in the PDB, the in-
teraction with the target sequence is already shown to be viable in a bi-
ological context. In addition, given this design strategy, the resulting
complementary peptides are expected to bind the target epitope by
ED
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Fig. 4. Development and validation of a real-time ELISA using DesAb-O for the quantification of Aβ42 oligomers in an aggregation reaction. (A) Illustration
of the experimental setup of the time-course ELISA. Samples from 5 μM Aβ42 aggregation reactions were collected at specific incubation times and loaded
onto an ELISA plate. The amounts of oligomers were determined from absorbance measurements upon incubation with DesAb-O and a commercial HRP-
conjugated anti-His tag antibody. (B) ELISA measurements taken at 0 h, 0.5 h (50% of the total aggregation time), and 2 h (plateau, 100% of the total
aggregation time) from a 5 μM Aβ42 aggregation reaction using DesAb-O (red), DesAb-Aβ18–24 (blue), and the commercial antibody 6E10 (gray). Data of each
antibody were normalized for the corresponding average value at t = 0. Error bars are representative of the SD. Statistical analysis was performed by ANOVA
with multiple comparisons (CI 95%, ****P < 0.0001; n.s., not significant). (C) Concentrations of monomers (gray), oligomers (red), and fibrils (blue) at varying
time points for a 5 μM Aβ42 aggregation reaction. (D) ThT aggregation assays of 3 μM Aβ42 alone (blue) or in the presence of fivefold molar excess bex-
arotene (red). (E) Time course ELISA of 3 μM Aβ42 alone (blue) or in the presence of fivefold molar excess bexarotene (red). Error bars are representative of
the SD. Individual data points are shown in SI Appendix, Fig. S4B.
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enforcing a β-strand–like conformation. Therefore, such complementary
peptides will be particularly effective in binding to solvent-exposed regions
of protein sequences that do not form persistent hydrogen bonds with other
parts of the protein molecule, such as in the case of disordered regions (22).
Protein Expression and Purification. The various complementary peptides
were grafted into the CDR3 of the DesAb scaffold bymeans ofmutagenic PCR
with phosphorylated oligonucleotides (21). The different DesAb constructs
were then expressed and purified using Ni2+ chromatography, as previously
described (21). Imidazole was finally removed using size-exclusion chromatography
with a HiLoad 16/600 Superdex 75 pg column (GE Healthcare). Protein
concentration was determined by absorbance measurement at 280 nm
using theoretical extinction coefficients calculated with ExPASy ProtParam
(34). Aβ40 (M1–40) and Aβ42 (M1–42) peptides were expressed in E. coli
BL21 (DE3) Gold Strain (Agilent Technologies) and purified as described
previously (8). Aliquots of purified Aβ42 and Aβ40 were lyophilized and
stored at −80 °C.
CD. Far-ultraviolet (UV) CD spectra of the DesAbs were recorded using a
Jasco J-810 spectropolarimeter equipped with a Peltier holder (Jasco UK Ltd),
A
B C D E
Fig. 5. Quantification of Aβ42 oligomers in C. elegans and mouse hippocampal tissue. (A) From left to right: plots showing body bends per minute of N2
(dashed gray line) and GMC101 (continuous black line) worms (n = 500 individual worms), NIAD-4 fluorescence intensities of GMC101 (blue bars) and N2
(white bars) worms (n = 30 individual worms), and ELISA absorbance of DesAb-O of GMC101 (red bars) and N2 (white bars) worms at different days of
adulthood. NIAD-4 fluorescence intensity was calculated as corrected total cell fluorescence using the ImageJ software (Methods). (B–E) Comparison of
different aggregate-detection assays for the hippocampus CA3 area from J20 (blue) and control wild-type (black) mice at 4, 9, and 18 mo of age. (B) NIAD-4
fluorescence from J20 (blue) and control wild-type (black) mice; representative fluorescence images are shown in the insets. The dashed line marks the
borders of the cell body layer in the CA3 region of the hippocampus. (Scale bars, 100 μm.) (C) Absorbance of an ELISA using DesAb-O from J20 (red) and
control wild-type (black) mice. (D) Absorbance of an ELISA using the monoclonal antibody 6E10 from J20 (gray) and control wild-type (black) mice. (E) Bar plot
of the NIAD-4 and DesAb-O signals of J20 mice from B and C divided by the 6E10 signals of D; all error bars represent SEs. Statistical analysis in A was
performed by ANOVA with multiple-comparison and in B–D with a t test (CI 0.95; *P≤0.05, **P≤0.01, ****P≤0.0001; n.s., not significant).
Aprile et al. PNAS | June 16, 2020 | vol. 117 | no. 24 | 13515
BI
O
PH
YS
IC
S
A
N
D
CO
M
PU
TA
TI
O
N
A
L
BI
O
LO
G
Y
using a 0.1-cm-pathlength cuvette. Samples contained 10 μM protein in
20 mM Tris pH 7.4, 100 mM NaCl. The far-UV CD spectra of all DesAbs were
recorded from 200 to 250 nm at 20 °C, and the spectrum of the buffer was
subtracted from the spectra of all DesAbs.
Aggregation Assays of Aβ42. The lyophilized Aβ42 peptide was dissolved in
6 M guanidinium, pH 8, and incubated for 3 h on ice. This solution was then
injected into a Superdex 75 10/300 Increase size-exclusion column (GE
Healthcare), and the peak corresponding to the monomeric Aβ42 peptide
was isolated and collected in low-binding test tubes (Corning) on ice (8).
Ninety micromoles of each aggregation sample were then pipetted into
black polystyrene 96-well half-area plates with clear bottoms and poly-
ethylene glycol coating (Corning). Plates were sealed to prevent evapora-
tion. Aggregation assays were performed at 37 °C under quiescent
conditions using a CLARIOstar plate reader (BMG Labtech). Fluorescence
emissions at 480 nm were recorded upon excitation at 440 nm through the
bottom of the plate every 2 min. Aggregations samples were prepared with
2 μM monomeric Aβ42 in the presence of different molar equivalents of
DesAb-O in 20 mM sodium phosphate, pH 8, 200 μM ethylenediaminetetra-
acetic acid (EDTA), 0.02% NaN3, and 20 μM ThT. For seeded experiments,
aggregation samples were prepared in the same manner with the addition of
0.4 μM preformed Aβ42 fibrils.
ELISA-Based Binding Screening of the Antibodies. Monomeric Aβ42 peptides
were aggregated at a protein concentration of 5 μM in 20 mM sodium
phosphate buffer (pH 8) and 200 μM EDTA under quiescent conditions.
Twenty-microliter aliquots were taken at the t50 (i.e., half-time) of aggre-
gation from aggregation reactions. Samples were then immobilized on a 96-
or 384-well Maxisorp ELISA plate (Nunc) with no shaking for 1 h at room
temperature. The plate was then washed three times with 20 mM Tris, pH
7.4, and 100 mM NaCl and incubated in 20 mM Tris, pH 7.4, 100 mM NaCl,
and 5% bovine serum albumin (BSA) under constant shaking overnight at
4 °C. The day after the plate was washed six times with 20 mM Tris, pH 7.4,
and 100 mM NaCl and then incubated with 30 μL solutions of 5 μM DesAb-O
under constant shaking either for 1 h at room temperature or overnight at
4 °C. At the end of this incubation, the plate was washed six times with
20 mM Tris, pH 7.4, and 100 mM NaCl and incubated with 30 μL solutions of
rabbit polyclonal 6x His tag horseradish peroxidase (HRP) conjugated
(Abcam) at a dilution of 1:4,000 in 20 mM Tris, pH 7.4, 100 mM NaCl, and 5%
BSA under shaking for 1 h at room temperature. Finally, the plate was
washed three times with 20 mM Tris, pH 7.4, and 100 mM NaCl, then twice
with 20 mM Tris, pH 7.4, 100 mM NaCl, and 0.02% Tween-20 and again three
times with 20 mM Tris, pH 7.4, and 100 mM NaCl. Finally, the amount of
bound DesAb-O was quantified by using 1-Step Ultra TMB-ELISA Substrate
Solution (Thermo Fisher Scientific), according to the manufacturer’s in-
structions, and the absorbance was measured at 450 nm by means of a
CLARIOstar plate reader (BMG Labtech).
Preparation for ThT/AF647–DesAb-O Fluorescence Imaging. Aliquots were
taken from aggregation reactions at 20-min intervals and imaged immedi-
ately. Borosilicate coverslips (22 × 22 mm, 630-2186; VWR) were cleaned for
1 h using argon plasma (PDC-002; Harrick Plasma). Frame-Seal slide chambers
(9 × 9 mm, SLF-0201; Bio-Rad) were affixed to the glass, and then washed
three times with filtered (0.2-μm syringe filter, 6780-1302; Whatman)
phosphate-buffered saline (PBS) buffer. A working solution containing
AF647-DesAb-O (1 nM) and ThT (5 μM) in filtered PBS (pH 7.4) was prepared
5 min prior to imaging. Aβ aliquots were diluted (500 nM), incubated on the
poly-L-lysine–coated coverslip for 5 min and then washed twice with filtered
PBS. The DesAb-ThT working solution (50 μL) was added to the cover slide
and incubated for 2 min prior to imaging.
DesAb–ThT Colocalization Imaging. Imaging experiments were carried out
with bespoke TIRF invertedmicroscope (Eclipse TE2000-U; Nikon) fittedwith a
Perfect Focus unit. Excitation of ThT and AF647 was achieved with either a
405-nm laser (LBX-405-50-CIR-PP; Oxxius) or 641-nm laser (Cube, 1150205;
Coherent), respectively. The beams were aligned parallel to the optical axis
and directed into an oil immersion objective lens (1.49 numerical aperture
[N.A.], 60×, Plan Apo, TIRF; Nikon) above the critical angle to ensure TIR at
the coverslip/sample (glass/water) interface. Fluorescence emission was also
collected by the same objective and selected by the presence of a dichroic
(Di01-R405/488/561/635; Semrock) and subsequently passed through appro-
priate emission filters (BLP01-488R-25, FF01-480/40-25, and FF01-676/37-25;
Semrock). Image stacks of the AF647 and ThT emission channels were col-
lected by sequential excitation of AF647 followed by ThT. Images were
recorded by an electron multiplying charge-coupled device (Evolve delta
512; Photometrics) with an electron multiplication gain of 250 analog-to-
digital units per photon running in frame transfer, clear presequence mode.
Each pixel on the image was 237 nm. Images from 27 different fields of view
were recorded at 50 ms for 200 frames in each emission channel using a
custom beanshell script through Micromanager software (v. 1.4).
DesAb–ThT Colocalization Image Analysis. Colocalization data were analyzed
with a bespoke ImageJmacro. Separate average intensity z-projections of ThT
and AF647 channels were created which results in single-frame images
representing the mean pixel intensities calculated for the total image stack.
Following this, points of intensity above a background threshold were lo-
cated, counted, and binarized. Pixels with a value of 1 in both the AF647 and
ThT images were identified as coincident points. Chance coincident spots
were extracted by performing a 90° rotation of the AF647 binary image and
subtracted from the total coincidence value. Percentage coincidence was
calculated as
%  coincidence = NDesAb−ThT
NDesAb−ThT + NDesAb( )( ) × 100.
AFM. We performed in air AFM measurements of the sample deposited on
glass, where TIRF measurements had been acquired. High-resolution images
(1,024 × 1,024 pixels) and phase-controlled maps (26) were collected using
an NX10 Atomic Force Microscope (Park Systems) under ambient conditions
and in amplitude modulation noncontact (NC-AM) mode. We imaged square
areas of 2 × 2 μm and 4 × 4 μm.We performed all of the measurements using
sharp cantilevers (PPP-NCHR; Park Systems) with resonance frequency of 330
kHz and a typical apical radius of 8 nm. The raw images were flattened using
the built-in software (XEI; Park Systems). To maintain consistency in the
subsequent statistical analysis, all images were processed using the same
parameters. The images were first flattened by a plane and then line-by-line
in first regression order. This second step was repeated until a flat baseline in
the line profile of the image was reached. During the process of flattening
of the images, the aggregates were masked from the calculation to avoid
modification and underestimation of their heights.
Sample Preparation for dSTORM Imaging. Glass cover slides (631-1570; VWR)
for single-aggregate fluorescence imaging were cleaned for 1 h using an
argon plasma (PDC-002; Harrick Plasma). Frame-Seal slide chambers (9 × 9
mm, SLF-0201; Bio-Rad) were attached to the cover slide. The slide was then
washed three times with filtered PBS prior to imaging. Gold nanoparticles in
PBS (100 nm, 753688; Sigma-Aldrich) were used as fiducial markers and were
diluted to 2 μM and incubated on the plasma-cleaned glass cover slides for
5 min followed by two gentle washes with PBS. Aβ42 aggregates were di-
luted to 2 μM in PBS + EDTA [(ethylenedinitrilo)tetraacetic acid] and in-
cubated on the cover slide for 5 min followed by two washes with PBS +
EDTA. dSTORM experiments were carried out in dSTORM buffer of PBS-Tris
(50 mM), glucose (0.5 mM), glucose oxidase (1.3 μM), catalase (2.2 μΜ), and
mercaptoethylamine (MEA) (50 mM). MEA was added to buffer immediately
prior to imaging. DesAb-AF647 (70 μM) was diluted into the STORM buffer
to a concentration of 100 pM and 50 μL added to the Aβ42-coated
cover slide.
dSTORM Imaging. Imaging was performed on a bespoke TIRF microscope
using a 641-nm excitation laser (Obis, 0.5 kW·cm−2; Coherent). The beam was
circularly polarized using a quarter-wave plate and then expanded, colli-
mated, and aligned parallel to the optical axis at the edge of an objective
lens (UPlanSApo, 100×, 1.4 N.A.; Olympus) mounted on an inverted optical
microscope (Ti2-E, Eclipse; Nikon Corporation). Emission was collected by the
same objective lens and separated from excitation light using a dichroic
mirror (Di01-R405/488/561/635; Semrock) and passed through appropriate
emission filters (FF01-692/40-25; Semrock). The fluorescence was then ex-
panded and focused on an electron-multiplying charge-coupled device
(Evolve 512 Delta; Photometrics) for imaging. Image stacks of 10,000 frames
were recorded in frame-transfer mode at 50 frames per second with an
exposure time of 20 ms. Each pixel on the final image was equal to 106 nm.
Super-resolution images were reconstructed using the Drift Calculator and
Peak Fit package (GDSC SMLM; University of Sussex) in ImageJ.
Microfluidic Diffusional Sizing. The binding affinity of DesAb-O for Aβ42 fibrils
was quantified in 20 mM sodium phosphate buffer (pH 8) by microfluidic
diffusional sizing, which measures the hydrodynamic radius of fluorescently
labeled species in their native state in solution (27). Aβ42 were sonicated (3/
3 s on/off cycles) for 1 min on ice with 50% power before use in the binding
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experiments. Samples containing 0.54 nM AF47-DesAb-O and various con-
centrations of Aβ42 fibrils in PBS were equilibrated at 22 °C for at least 17 h.
The hydrodynamic radius of AF647-DesAb-O at various concentrations of
Aβ42 fibrils was recorded using a Fluidity One-W instrument (Fluidic Ana-
lytics Ltd) between 27 and 28 °C.
The dissociation constant Kd was calculated by direct nonlinear regression
based on the fractional saturation as a function of the concentration of total
ligand added:
r = Ltot[ ] + n* Btot[ ] + KD
2
−
̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅
Ltot[ ] + n* Btot[ ] + KD
2
( )2 − Ltot[ ]*n* Btot[ ]√⎛⎜⎜⎜⎝ ⎞⎟⎟⎟⎠
*
Δrtot
n* Btot[ ] + ro
with Δrtot, ro, and r being the maximum change in the DesAb-O radius
between the bound and unbound state, the radius in the absence of any
ligand, and the measured radius at fibril mass concentration [Ltot], re-
spectively. Furthermore, [Btot] and n are the DesAb-O concentration used
and the number of fibril binding sites per DesAb-O molecule. Since the
binding mode of DesAb-O with fibrils is not known, the effective binding
affinity was determined through fitting the molar stoichiometry of DesAb-O
and fibrils, finding that on average about 200 Aβ monomers within the fi-
brils bind each DesAb-O molecule, with low micromolar affinity.
ELISA with Aliquots from Aggregation Reactions. Twenty-microliter aliquots
were taken at specific incubation times and immobilized on a 96- or 384-well
Maxisorp ELISA plate (Nunc) with no shaking for 1 h at room temperature.
Experiments were then performed as described above (ELISA-Based
Screening of the Antibodies). Experiments in the presence of the com-
pound bexarotene were performed using the same protocol on aggregation
reactions supplemented with 5 molar excess bexarotene.
Strains of C. elegans. The following strains of C. elegans were used: dvIs100
[unc-54p::A-beta-1-42::unc-54 3′-UTR + mtl-2p::GFP] (GMC101), which pro-
duces constitutive expression of green fluorescent protein (GFP) in intestinal
cells, and unc-54p::A-beta-1-42, which expresses full-length human Aβ42 in
body-wall muscle cells that aggregates in vivo; shifting L4 or young adult
animals from 20 °C to 25 °C causes paralysis (29). C. elegans var Bristol (N2)
was used as a control strain. Generation time is about 3 d. The control strain
was isolated from mushroom compost near Bristol, England (35).
Media for C. elegans. Standard conditions were used for the propagation of C.
elegans. Briefly, the animals were synchronized by hypochlorite bleaching,
hatched overnight in M9 (3 g/L KH2PO4, 6 g/L Na2HPO4, 5 g/L NaCl, and 1 μM
MgSO4) buffer, and subsequently cultured at 20 °C on nematode growth
medium (NGM) (CaCl2 1mM, MgSO4 1 mM, cholesterol 5 μg/mL, 250 μM
KH2PO4, pH 6, agar 17 g/L, NaCl 3 g/L, and casein 7.5 g/L) plates seeded with
the E. coli strain OP50. Saturated cultures of OP50 were grown by in-
oculating 50 mL of LB medium (tryptone 10 g/L, NaCl 10 g/L, and yeast ex-
tract 5 g/L) with OP50 and incubating the culture for 16 h at 37 °C. NGM
plates were seeded with bacteria by adding 350 μL of saturated OP50 to
each plate and leaving the plates at 20 °C for 2 to 3 d. On day 3 after syn-
chronization, the animals were placed on NGM plates containing 5-fluoro-2′
deoxy-uridine (FUDR) (6.83 nM, unless stated otherwise) to inhibit the
growth of offspring. FUDR plates were seeded with bacteria by adding
350 μL of 10× concentrated OP50 solution to ensure starvation did not occur
for the lifespan of the worm. Concentrated OP50 solution was obtained by
centrifuging 1 L of saturated OP50 culture at 5,000 rpm for 15 min and
suspending the resultant pellet in 100 mL sterile water.
Staining of the Aggregates Using the Fluorescent Probe NIAD-4. To visualize
the amount of aggregates in the worms, live transgenic were incubated with
1 μM NIAD-4 (0.1% dimethyl sulfoxide in M9 buffer) for 4 h at room tem-
perature. After staining, animals were allowed to recover on NGM plates for
about 24 h to allow destaining via normal metabolism. Stained animals were
mounted on 2% agarose pads containing 40 mM NaN3 as anesthetic on glass
microscope slides for imaging. Images were captured using a Zeiss Axio
Observer D1 fluorescence microscope (Carl Zeiss Microscopy GmbH) with a
20× objective and a 49004 ET-CY3/TRITC filter (Chroma Technology Corp.).
Fluorescence intensity was calculated using ImageJ and then normalized as
the corrected total cell fluorescence. Only the head region was considered
because of the high background signal in the guts. All experiments were
carried out in triplicate, and the data from one representative experiment
are shown.
Automated Motility Assay on Agar Plates and Imaging of the Aggregates. All C.
elegans populations were cultured at 20 °C and developmentally synchro-
nized from a 4-h egg lay. At 64 to 72 h after egg lay (time 0), individuals
were shifted to 24 °C and transferred to FUDR plates and body movements
were assessed over the times indicated. Videos were analyzed using a
custom-made tracking code.
ELISA with C. elegans Protein Extracts. GMC101 and N2 worms were incubated
on FUDR plates until days 0, 1, 3, 5, 7, and 10 of adulthood, according to what
is reported in the text for each experiment. At a specific time the worms were
washed out of the plates and snap-frozen using liquid nitrogen. For sample
preparation, around 1,000 animals were thawed and resuspended in 500 μL
PBS supplemented with EDTA-free protease inhibitor tablets 1× (Roche),
after which they were sonicated (5 × 45 s, 50% cycles, 50% maximum power
on ice) using a Bandelin Sonopuls HD 2070. After sonication, the lysates were
centrifuged at maximal speed using a bench centrifuge and 20 μL of su-
pernatant (5 μg) were loaded on a 96 Maxisorp ELISA plate (Nunc) with no
shaking overnight at 4 °C. ELISAs were conducted as described above (ELISA-
Based Screening of the Antibodies).
Use and Care of the Mice. Experiments were performed according to the
Animals Scientific Procedures Act UK (1986). Tg(PDGFB-APPSwInd)20Lms/
2Mmjax (J20) heterozygous mice were housed at University College London,
maintained on a 12-h light/dark cycle and provided with food and water for
ad libitum consumption. Transgenic or nontransgenic female littermates (16
to 18 mo old) were used for this experiment (n = 3 per group).
Immunofluorescence Staining. J20 mouse brains were collected, immediately
fixed overnight at 4 °C with 4% paraformaldehyde in PBS, then washed
twice with PBS and immersed in 30% sucrose/PBS for 2 d. Next, brain samples
were frozen in precooled isopentane on dry ice, and 50-μm sections were cut
on a cryostat and stored in ethylene glycol-based cryoprotectant (30%
glycerol and 30% ethylene glycol in 0.1 M sodium/potassium phosphate
buffer, pH 7.4). Brain sections were washed twice in PBS and then incubated
for 30 min with 10 μM NIAD-4 (0.1% dimethyl sulfoxide [DMSO] and 0.5%
Triton in PBS). The samples were washed three times with PBS. Finally, brain
slices were mounted in Fluoromount-G (SouthernBiotech) on a glass slide for
imaging. Images of the hippocampus area were captured using a Leica SP8
confocal microscope. NIAD-4 fluorescence was excited at 488 nm and emis-
sion recorded at 550 to 650 nm. Images were taken using a 20× (N.A. 0.72)
dry objective, with 1,024 × 1,024 image resolution and 15 z-steps of 0.5 μm.
ELISA with Mouse Protein Extracts. Thirty-microliter aliquots (5 μg) were
immobilized on a 96 Maxisorp ELISA plate (Nunc) with no shaking overnight
at 4 °C. Experiments were then performed as described above (ELISA-Based
Screening of the Antibodies).
Preparation of Aβ40 and α-Synuclein Oligomers. For the oligomers of Aβ40,
lyophilized Aβ40 (1 mg/mL) was solubilized overnight in 300 μL hexa-
fluoroisopropanol. Solvent was gently evaporated off with nitrogen and
protein resuspended in 100% DMSO. Two sonication steps of 10 min were
performed, after which the protein was resuspended at 100 μM in 20 mM
sodium phosphate buffer and 200 μM ZnCl2, pH 6.9, for 20 h at 20 °C.
Samples were centrifuged (15,000 rcf, 20 °C, 15 min) and the supernatant
was removed. Oligomers were resuspended in buffer (20 mM Tris and
100 mM NaCl) with thorough mixing. For the oligomers of α-synuclein, 6 mg
of lyophilized protein was resuspended in PBS to give a final concentration
of 800 μM and passed through a 0.22-μm cutoff filter immediately before
incubation at 37 °C for 20 under quiescent conditions. Small fibrils were
removed by ultracentrifugation for 1 h at 90,000 rpm (TLA-120.2 Beckman
rotor). The excess of monomeric protein and the low levels of small oligo-
mers were removed by filtration (using 100-kDa cutoff membranes).
ANS Binding Measurements. Ten-micromolar oligomers (in monomer equiv-
alents) were incubated for 2 h in the absence and presence of an equimolar
concentration of the different DesAbs at 20 °C. Subsequently, ANS
(Sigma-Aldrich) was added to a final concentration of 30 μM (i.e., threefold
excess dye). Emission spectra were recorded using a plate reader (BMG
Labtech) with excitation at 380 nm. Duplicate samples are shown repre-
sentative of three independent experiments that gave consistent results.
ELISA with Aβ40 Oligomers. Forty microliters of 5 μM DesAb solutions were
used to coat the wells of a 96-well Maxisorp ELISA plate (Nunc) with no
shaking for 1 h at room temperature. The plate was then washed three
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times with PBS and incubated in PBS and 5% BSA under constant shaking
overnight at 4 °C. The day after the plate was washed six times with PBS and
then incubated with 40-μL solutions of 5 μM oligomers in PBS under constant
shaking either for 1 h at room temperature or overnight at 4 °C. At the end
of this incubation, the plate was washed six times with PBS and incubated
with 40-μL solutions of the mouse monoclonal anti-Aβ antibody [6E10]
(1:2,000 dilution; Absolute Antibody Ltd). After six additional washes with
PBS and 0.02% Tween-20, the plate was incubated with 40 μL of goat anti-
mouse IgG (H+L) secondary antibody and HRP conjugate (1:2,000 dilution;
Life Technologies) in PBS and 5% BSA for 1 h at room temperature. Finally,
the plate was washed six times with PBS and 0.02% Tween-20 and bound
oligomers were quantified by using 1-Step Ultra TMB-ELISA Substrate So-
lution (Thermo Fisher Scientific) according to the manufacturer’s instructions
and the absorbance at 450 nm was measured by means of a CLARIOstar
plate reader (BMG Labtech).
Dot-Blot with Aβ40 Oligomers. Solutions of DesAb-O (4 and 2 μM) were
spotted (3.5 μL) on a 0.2-μm-pore-size nitrocellulose membrane (GE
Healthcare). As negative control, samples with same amounts of DesAb-
PYGSMYVHS, which showed the weakest binding to Aβ40 oligomers in in
the ANS binding measurements, were used. The blots were blocked in PBS
and 5% BSA overnight at 4 °C. Then, they were incubated in solutions
containing 5 μM Aβ40 oligomers in PBS overnight at 4 °C. Blots with bound
oligomers were then probed with the mouse monoclonal anti-Aβ antibody
[6E10] (1:2,000 dilution; Absolute Antibody Ltd) and with goat anti-mouse
IgG (H+L) secondary antibody and AF488 conjugate (1:5,000 dilution; Life
Technologies).
.
Kinetic Analysis. The time evolution of the total fibril mass, M(t), in the ab-
sence of seeds is described by the following integrated rate law:
M t( )
M ∞( ) = 1 −
B+ + C+
B+ + C+ekt
B− + C+ekt
B− + C+( )
k2∞
kkȣ∞
e−k∞t ,
where the kinetic parameters B+, C+, k, k∞, and k2∞ have been previously
described in detail (8) and are functions of the two combinations of the
microscopic rate constants k+kn and k+k2, where kn, k+, and k2 are the pri-
mary nucleation, elongation, and secondary nucleation rate constants,
respectively.
The above equation was used to identify the nucleation rate constants
inhibited by the DesAb-O to describe the macroscopic aggregation profiles
shown in SI Appendix, Figs. S5–S7 and comparing the set of microscopic rate
constants k+kn and k+k2 to describe the time evolution of the fibril formation
in the absence and presence of antibody.
The apparent rate constant k+ was derived as the rate of formation of
fibrils within the first 20% of monomer conversion, r = 2k + P0m, where P0 is
the number of seeds introduced in the system and m is the initial monomer
concentration. The relative decrease in the apparent rate constant k+ was
evaluated by dividing the rate in the presence of DesAb-O with the value
calculated in its absence. Finally, the decreases in kn and k2 were calculated
by dividing the decreases in k+k2 and k+kn obtained under unseeded con-
ditions by the decrease in k+ derived from the seeded aggregation profiles.
ITC. Measurements were performed on a MicroCal iTC200 (Malvern Pan-
alytical Ltd) at 25 °C. The DesAb-O (100 μM) was injected 16 times into a
solution containing 10 μM of either monomers of Aβ40, stabilized Aβ40
oligomers, or stabilized oligomers of α-synuclein. The first injection was 0.2
μL; all other injections were 2 μL. Aβ40 experiments were carried out in
20 mM Tris, pH 7.4, and 100 mM NaCl. Additionally, all solutions for the
experiments involving monomeric Aβ40 contained 0.05% DMSO to ensure
that the peptide was in its monomeric form. α-Synuclein solutions were
carried out in standard PBS. Each injection occurred at 3-min intervals. Heats
of dilution, obtained by separately injecting the antibody into the corre-
sponding buffer and the buffer into either the monomer or oligomer so-
lutions, were subtracted from the final data. The corrected heats were
divided by the number of moles injected and analyzed using Origin 7.0
software (OriginLab).
Data Availability Statement. All data are provided in the main text and
SI Appendix.
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